Hot Investor Mandate: Seed Fund Invests in Pre-IND Therapeutics

29 Aug

A newly launched investment fund seeks to provide seed financing in promising therapeutics to help establish proof of concept for new clinical compounds and to identify novel clinical uses for existing therapeutics. The firm’s founder has robust experience with investing in and operating biotechnology and healthcare companies, and seeks to leverage this expertise to help foster innovation. The firm’s initial size of investment will be in the range of $250K to $1M. The firm has been in active discussions with academia and corporate-funded researchers to identify promising early-stage therapeutic candidates. In addition to traditional investment approaches, the firm is interested in new company creation based on promising drug candidates. For traditional investment, the firm will prioritize companies that are based in the USA, but will seek global assets for potential in-licensing and company creation around this IP. The firm expects to invest and work with 5-10 companies across the fund.

The firm is primarily interested in small molecule therapeutics, as the cost of characterizing new biologics and cell therapies is outside of its investment scale. The firm is seeking very early-stage, pre-IND assets, and will assist with successful IND filing and completion of required studies. The firm primarily seeks therapeutics for rare diseases that qualify for orphan drug designation, but apart from that the firm is indication agnostic.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: